Immunomedics Inc. is preparing to launch Trodelvy (sacituzumab govitecan), the first antibody-drug conjugate for triple-negative breast cancer (TNBC) and its first commercial product, despite the challenges of launching a new drug in the current COVID-19 pandemic. The company laid out the strategy it will use to drive rapid brand awareness and adoption of Trodelvy and establish Immunomedics as a respected oncology partner during an investor call.
Trodelvy received accelerated approval from the US Food and Drug Administration on 22 April for metastatic TNBC after at least...
